Kiadis Pharma announces that three abstracts related to its K-NK-cell therapy platform have been accepted at the ASCO 2020 Virtual Annual Meeting
Amsterdam, The Netherlands, May 13, 2020 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces three abstracts supporting the potential of the Company’s K-NK cell therapy program to treat relapsed/refractory acute myeloid leukemia (R/R ML) have been accepted at the American Society of Clinical Oncology (ASCO) Virtual Annual Meeting taking place May 29 – 31, 2020.
The ASCO abstracts are now available at https://meetings.asco.org/am/virtual-format. Details of the presentations are as follows:
· Abstract #3025 has been accepted as a poster and presents clinical data of a subset of R/R AML patients with CNS disease treated with FC21-NK cells in a phase I/II study (NCT02809092).
Title: CD56bright/CD16bright NK-cell adoptive immunotherapy in patients with concurrent CNS disease and relapsed or refractory (R/R) AML.
Presenter: Lucia Silla
Session title: Developmental Therapeutics—Immunotherapy
· Abstract #TPS7562 is a ‘trials in progress’ poster summarizing how off-the-shelf FC21-NK is investigated to treat R/R AML and MDS patients (NCT04220684). This study is sponsored by Ohio State University and supported by Kiadis.
Title: A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Off-the-Shelf, Natural Killer Cells for Relapse/Refractory Acute Myeloid Leukemia
Presenter: Sumi Vasu
Session title: Trials in Progress poster #335
· Abstract e15018 was accepted for publication only and contains pre-clinical data that show CD38 knock-out of FC21-NK cells limits NK cell fratricide and enhances the overall activity against Multiple Myeloma cells in presence of an anti-CD38 antibody.
Title: Impact of CD38 Knockout in NK Cells on Daratumumab-mediated Cytotoxicity and Cellular Metabolism.
Presenter: Yuya Nagai
Session title: Online publication only available on May 13, 2020, 5:00 p.m. ET
Kiadis Pharma contacts
Maryann Cimino, Sr. Manager, Corporate Affairs
Tel: +1 (617) 710-7305
|Optimum Strategic Communications:
Mary Clark, Supriya Mathur, Hollie Vile
Tel: +44 203 950 9144
David Brilleslijper (Amsterdam)
Tel: +31 610 942 514
About Kiadis Pharma’s K-NK-Cell Therapies
Kiadis Pharma’s NK-cell programs consist of off-the-shelf and haplo donor cell therapy products for the treatment of liquid and solid tumors as adjunctive and stand-alone therapies.
The Company’s NK-cell PM21 particle technology enables improved ex vivo expansion and activation of anti-cancer cytotoxic NK-cells supporting multiple high-dose infusions. Kiadis Pharma’s proprietary off-the-shelf NK-cell platform is based on NK-cells from unique universal donors. The Kiadis Pharma off-the-shelf K-NK platform can make NK-cell therapy product rapidly and economically available for a broad patient population across a potentially wide range of indications.
Kiadis Pharma is clinically developing K-NK003 for the treatment of relapse/refractory acute myeloid leukemia. The Company is also developing K-NK002, which is administered as an adjunctive immunotherapeutic on top of HSCT and provides functional, mature and potent NK-cells from a haploidentical family member. In addition, the Company has pre-clinical programs evaluating NK-cell therapy for the treatment of solid tumors.
About Kiadis Pharma
Founded in 1997, Kiadis Pharma is building a fully integrated biopharmaceutical company committed to developing innovative therapies for patients with life-threatening diseases. With headquarters in Amsterdam, the Netherlands, and offices and activities across the United States, Kiadis Pharma is reimagining medicine by leveraging the natural strengths of humanity and our collective immune system to source the best cells for life.
Kiadis Pharma is listed on the regulated market of Euronext Amsterdam and Euronext Brussels since July 2, 2015, under the symbol KDS. Learn more at www.kiadis.com.
Forward Looking Statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect Kiadis Pharma’s or, as appropriate, Kiadis Pharma’s officers’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of known and unknown risks, uncertainties and assumptions that could cause actual results, performance, achievements or events to differ materially from those expressed, anticipated or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, regulation, competition and technology, can cause actual events, performance, achievements or results to differ significantly from any anticipated or implied development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, Kiadis Pharma expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or projections, or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither Kiadis Pharma nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the anticipated or implied developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.